- Home
- MYGN vs PFL Comparison
MYGN vs PFL Comparison
Compare MYGN & PFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MYGN | PFL |
|---|---|---|
| Founded | 1991 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.9M | 379.3M |
| IPO Year | 1996 | 2003 |
Fundamental Metrics
Financial Performance| Metric | MYGN | PFL |
|---|---|---|
| Price | $4.60 | $8.43 |
| Analyst Decision | Hold | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $8.06 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 171.1K |
| Earning Date | 05-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.53% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $771,400,000.00 | N/A |
| Revenue This Year | $7.26 | N/A |
| Revenue Next Year | $5.09 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.33 | N/A |
| 52 Week Low | $3.76 | $7.11 |
| 52 Week High | $11.44 | $8.70 |
Technical Indicators
Market Signals| Indicator | MYGN | PFL |
|---|---|---|
| Relative Strength Index (RSI) | 37.54 | 52.97 |
| Support Level | $3.76 | $8.42 |
| Resistance Level | $5.66 | $8.51 |
| Average True Range (ATR) | 0.35 | 0.06 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 32.61 | 60.53 |
Price Performance
Historical ComparisonAbout MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About PFL PIMCO Income Strategy Fund Shares of Beneficial Interest
PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. The company seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.